LDE225 --- Hedgehog Antagonist

Bioss Antibodies

LDE225 --- Hedgehog Antagonist [956697-53-3]

16

Research Use Only

98.0

LDE225 is a potent and specific Hedgehog pathway inhibitor through binding and antagonizing Smo with an IC50 of 11 nM. It is currently in the clinical trials to treat cancers. It inhibited Hh signaling and induces tumor regression in animal models of medulloblastoma. It sensitized chemotherapy-resistant ovarian cancer cell lines to paclitaxel, but not to carboplatin. In one of the clinical trials, treatment with 0.75% LDE225 cream in NBCCS patients was very well tolerated and caused BCC regression.

-20°C

51202000